Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/platinum-resistant-and-refractory-ovarian-cancer-yMV7h6zPPX
References (80)
-
D. Tresukosol, A. Kudelka, C. Leon, C. Edwards, R. Freedman, R. Mante, M. Hord, J. Kavanagh (1996)
Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer.European journal of gynaecological oncology, 17 3
-
M. Gore, A. Oza, G. Rustin, J. Malfetano, H. Calvert, D. Clarke‐Pearson, J. Carmichael, G. Ross, R. Beckman, S. Fields (2002)
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer.European journal of cancer, 38 1
-
P. Rose, N. Fusco, L. Fluellen, M. Rodriguez (1998)
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 4
-
D. Lau, L. Xue, L. Young, P. Burke, A. Cheung (1999)
Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer.Cancer biotherapy & radiopharmaceuticals, 14 1
-
I. Ringel, S. Horwitz (1991)
Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.Journal of the National Cancer Institute, 83 4
-
D. Belotti, V. Vergani, T. Drudis, P. Borsotti, Maria Pitelli, G. Viale, R. Giavazzi, G. Taraboletti (1996)
The microtubule-affecting drug paclitaxel has antiangiogenic activity.Clinical cancer research : an official journal of the American Association for Cancer Research, 2 11
-
J. Thigpen, J. Blessing, H. Ball, S. Hummel, R. Barrett (1994)
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 9
-
K. Hatch, J. Beecham, J. Blessing, W. Creasman (1991)
Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second‐line therapy in 105 patientsCancer, 68
-
P. Dombernowsky, N. Nissen, V. Larsen (1972)
Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors.Cancer chemotherapy reports, 56 1
-
B. Lund, O. Hansen, Karen Theilade, Mogens Hansen, J. Neijt (1994)
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.Journal of the National Cancer Institute, 86 20
-
M. Cohen, P. Creaven, F. Tejada, H. Hansen, F. Muggia, A. Mittelman, Selawry Os (1975)
Phase I clinical trial of isophosphamide (NSC-109724).Cancer chemotherapy reports, 59 4
-
Maurie Markman, J. Blessing, David Moore, H. Ball, S. Lentz (1998)
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.Gynecologic oncology, 69 3
-
P. Sørensen, M. Høyer, A. Jakobsen, H. Malmström, H. Havsteen, K. Bertelsen (2001)
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.Gynecologic oncology, 81 1
-
M. Markman, K. Iseminger, K. Hatch, W. Creasman, W. Barnes, B. Dubeshter (1996)
Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.Gynecologic oncology, 62 1
-
M. Seymour, JL Mansi, Cj Gallagher, ME Gore, PG Harper, Trj Evans, PM Edmonds, M. Slevin (1994)
Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.British Journal of Cancer, 69
-
M. Markman, R. Rothman, T. Hakes, B. Reichman, W. Hoskins, S. Rubin, W. Jones, L. Almadrones, J. Lewis (1991)
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 3
-
W. Mcguire, W. Hoskins, W. Hoskins, M. Brady, P. Kucera, E. Partridge, K. Look, D. Clarke‐Pearson, Martin Davidson (1996)
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancerInternational Journal of Gynecology & Obstetrics, 54
-
P. Huang, S. Chubb, S. Chubb, L. Hertel, G. Grindey, W. Plunkett (1991)
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.Cancer research, 51 22
-
K. Zanotti, J. Belinson, A. Kennedy, K. Webster, M. Markman (2000)
Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.Gynecologic oncology, 79 2
-
J. Díaz, J. Andreu (1993)
Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition.Biochemistry, 32 11
-
P. Rose, J. Blessing, A. Mayer, H. Homesley (1998)
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 2
-
M. Besenval, M. Delgado, Demarez Jp, A. Krikorian (1989)
Safety and tolerance of Navelbine in phase I-II clinical studies.Seminars in oncology, 16 2 Suppl 4
-
G. Creemers, G. Bolis, M. Gore, G. Scarfone, Á. Lacave, J. Guastalla, R. Despax, G. Favalli, R. Kreinberg, S. Belle, I. Hudson, J. Verweij, W. Huinink (1996)
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 12
-
S. Johnson, P. Harper, G. Hortobagyi, P. Pouillart (1996)
Vinorelbine: an overview.Cancer treatment reviews, 22 2
-
A. Gordon, J. Fleagle, D. Guthrie, D. Parkin, M. Gore, Á. Lacave (2001)
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 14
-
E. Eisenhauer, W. Huinink, K. Swenerton, L. Gianni, J. Myles, M. Burg, I. Kerr, J. Vermorken, K. Buser, N. Colombo, M. Bacon, Pedro Santabárbara, N. Onetto, B. Winograd, R. Canetta (1994)
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 12
-
M. Markman, James Hall, D. Spitz, S. Weiner, L. Carson, L. Le, M. Baker (2002)
Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 9
-
W. Huinink, M. Gore, J. Carmichael, A. Gordon, J. Malfetano, I. Hudson, C. Broom, C. Scarabelli, N. Davidson, M. Spanczynski, G. Bolis, H. Malmstrom, R. Coleman, S. Fields, J. Héron (1997)
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 6
-
A. Gordon, C. Granai, P. Rose, J. Hainsworth, A. López, C. Weissman, Rosemary Rosales, Timothy Sharpington (2000)
Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 17
-
D. Budman (1997)
Vinorelbine (Navelbine): a third-generation vinca alkaloid.Cancer investigation, 15 5
-
H. Guchelaar, C. Napel, E. Vries, N. Mulder (1994)
Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review.Clinical oncology (Royal College of Radiologists (Great Britain)), 6 1
-
Michael Rodriguez, P. Rose (2001)
Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.Gynecologic oncology, 83 2
-
John Kavanagh, A. Kudelka, C. León, D. Tresukosol, M. Hord, M. Finnegan, E. Kim, D. Varma, A. Forman, Paul Cohen, C. Edwards, R. Freedman, C. Verschraegen (1996)
Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.Clinical cancer research : an official journal of the American Association for Cancer Research, 2 5
-
G. Scarfone, A. Villa, F. Parazzini, C. Sciatta, G. Polverino, G. Bolis (1999)
A Phase I-II Trial of High-dose Ifosfamide in Patients with Ovarian Cancer Refractory or Resistant to Platinum and/or Paclitaxel-containing ChemotherapyTumori Journal, 85
-
F. Muggia, J. Hainsworth, S. Jeffers, P. Miller, S. Groshen, M. Tan, L. Roman, B. Uziely, L. Muderspach, A. Garcia, A. Burnett, F. Greco, C. Morrow, L. Paradiso, L. Liang (1997)
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 3
-
J. Extra, F. Rousseau, R. Bruno, M. Clavel, N. Bail, Michel Marty (1993)
Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.Cancer research, 53 5
-
M. Gore, I. Fryatt, E. Wiltshaw, T. Dawson (1990)
Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.Gynecologic oncology, 36 2
-
J. Ponce, Y. Flores-Picazo, J. Pérez-Urizar, G. Castañeda-Hernández, J. Zinser-Sierra, A. Dueñas-González, E. Calderón-Flores, B. Segura‐Pacheco, J. Garza-Salazar (1999)
Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives.Archives of medical research, 30 3
-
R. Fleming (1997)
An Overview of Cyclophosphamide and Ifosfamide PharmacologyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 17
-
M. Donato, D. Gershenson, J. Wharton, C. Ippoliti, A. Alemán, D. Bodurka-Bevers, M. Bevers, T. Burke, C. Levenback, J. Wolf, R. Freedman, R. Bast, J. Gajewski, R. Champlin (2001)
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.Gynecologic oncology, 82 3
-
M. Markman, A. Kennedy, K. Webster, B. Kulp, G. Peterson, J. Belinson (1997)
Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.Gynecologic oncology, 65 3
-
P Hoskins, K. Swenerton (1994)
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 1
-
J. Edmonson, D. Decker, G. Malkasian, M. Webb, E. Jørgensen (1978)
Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.Gynecologic oncology, 6 1
-
Robert Ozols, J. Thigpen, J. Dauplat, N. Colombo, M. Piccart, K. Bertelsen, L. Levin, Bente Lund (1993)
Advanced ovarian cancer. Dose intensity.Annals of oncology : official journal of the European Society for Medical Oncology, 4 Suppl 4
-
M. Bookman, H. Malmström, G. Bolis, A. Gordon, A. Lissoni, J. Krebs, S. Fields (1998)
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 10
-
M. Markman, B. Reichman, T. Hakes, W. Jones, J. Lewis, S. Rubin, L. Almadrones, W. Hoskins (1991)
Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 10
-
G. Bolis, F. Parazzini, G. Scarfone, A. Villa, M. Amoroso, E. Rabaiotti, A. Polatti, Simona Reina, E. Pirletti (1999)
Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer.Gynecologic oncology, 72 1
-
B. Lund, J. Neijt (1996)
Gemcitabine in cisplatin-resistant ovarian cancer.Seminars in oncology, 23 5 Suppl 10
-
C. Verschraegen, T. Sittisomwong, A. Kudelka, E. Guedes, M. Steger, T. Nelson-Taylor, Monique Vincent, Roger Rogers, E. Atkinson, John Kavanagh (2000)
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 14
-
P. Wiernik, E. Greenwald, H. Ball, J. Young, S. Vogl (1998)
High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Eastern Cooperative Oncology Group Study PD884.American journal of clinical oncology, 21 6
-
R.F. Ozols (1999)
Oral etoposide for the treatment of recurrent ovarian cancerDrugs, 58
-
R. Slayton, W. Creasman, W. Petty, B. Bundy, J. Blessing (1979)
Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.Cancer treatment reports, 63 11-12
-
G. Blackledge, F. Lawton, C. Redman, K. Kelly (1989)
Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.British Journal of Cancer, 59
-
D. Fennelly, C. Aghajanian, F. Shapiro, C. O'flaherty, M. Mckenzie, C. O'Connor, W. Tong, L. Norton, D. Spriggs (1997)
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 1
-
R. Ozols (2002)
Recurrent ovarian cancer: evidence-based treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 5
-
M. Markman, M. Markman, A. Kennedy, A. Kennedy, G. Sutton, G. Sutton, J. Hurteau, J. Hurteau, K. Webster, K. Webster, G. Peterson, G. Peterson, B. Kulp, B. Kulp, J. Belinson, J. Belinson (1998)
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.Gynecologic oncology, 70 2
-
M. Burg, R. Wit, W. Putten, A. Logmans, W. Kruit, G. Stoter, J. Verweij (2002)
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancerBritish Journal of Cancer, 86
-
R. Ozols, M. Gore, C. Tropé, S. Grénman (1999)
Intraperitoneal treatment and dose-intense therapy in ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 10 Suppl 1
-
M. Piccart, M. Gore, W. Huinink, A. Oosterom, J. Verweij, J. Wanders, Hilary Frankli, M. Bayssas, S. Kaye (1995)
Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.Journal of the National Cancer Institute, 87 9
-
M. Markman, A. Kennedy, K. Webster, B. Kulp, G. Peterson, J. Belinson (2000)
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.Gynecologic oncology, 79 1
-
Maurie Markman, M. Bookman (2000)
Second-line treatment of ovarian cancer.The oncologist, 5 1
-
S. Wilailak, V. Linasmita, S. Srisupundit (2001)
Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancerAnti-Cancer Drugs, 12
-
W. Mcguire, E. Rowinsky, N. Rosenshein, F. Grumbine, D. Ettinger, D. Armstrong, R. Donehower (1989)
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.Annals of Internal Medicine, 111
-
R. Burger, P. Disaia, J. Roberts, M. O'Rourke, D. Gershenson, H. Homesley, S. Lichtman, W. Barnes, D. Moore, B. Monk (1999)
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer.Gynecologic oncology, 72 2
-
P. Rose, N. Gordon, N. Fusco, L. Fluellen, M. Rodriguez, S. Ingalls, C. Hoppel (2000)
A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.Gynecologic oncology, 78 2
-
A. Maskens, J. Armand, Á. Lacave, R. Jager, H. Hansen, J. Wolff (1981)
Phase II clinical trial of VP-16-213 in ovarian cancer.Cancer treatment reports, 65 3-4
-
W.P. McGuire, W.J. Hoskins, M.F. Brady (1996)
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancerN Engl J Med, 334
-
G. Bolis, G. Scarfone, G. Giardina (2001)
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer: Associazione per la Ricerca in Ginecologia OncologiaGynecol Oncol, 81
-
M. Bookman (1999)
Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.The oncologist, 4 2
-
Harnett Wl (1953)
The relation between delay in treatment of cancer and survival rate.British Journal of Cancer, 7
-
D. Clarke‐Pearson, L. Le, T. Iveson, C. Whitney, P. Hanjani, G. Kristensen, J. Malfetano, R. Beckman, G. Ross, S. Lane, M. DeWitte, S. Fields (2001)
Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 19
-
M. Markman, T. Hakes, B. Reichman, J. Lewis, S. Rubin, W. Jones, L. Almadrones, Frank Pizzuto, W. Hoskins (1992)
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 2
-
P. Sørensen, P. Pfeiffer, K. Bertelsen (1995)
A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.Gynecologic oncology, 56 1
-
H. Cortés-Funes, Christopher Martin, R. Abratt, B. Lund (1997)
Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancerAnti-Cancer Drugs, 8
-
E. Bajetta, A. Leo, L. Biganzoli, L. Mariani, F. Cappuzzo, M. Bartolomeo, N. Zilembo, S. Artale, E. Magnani, L. Celio, R. Buzzoni, C. Carnaghi (1996)
Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 9
-
J. Kavanagh, D. Tresukosol, C. Edwards, R. Freedman, C. León, A. Fishman, R. Mante, M. Hord, A. Kudelka (1995)
Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 7
-
Prudence Francis, J. Schneider, L. Hann, C. Balmaceda, Richard Barakat, M. Phillips, T. Hakes (1994)
Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 11
-
J. Ahlgren, N. Ellison, R. Gottlieb, F. Laluna, J. Lokich, P. Sinclair, W. Ueno, G. Wampler, K. Yeung, D. Alt (1993)
Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 10
-
G. Bolis, G. Scarfone, G. Giardina, A. Villa, G. Mangili, M. Melpignano, M. Presti, S. Tateo, M. Franchi, F. Parazzini (2001)
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.Gynecologic oncology, 81 1
-
R. Jong, N. Mulder, D. Dijksterhuis, E. Vries (1995)
Review of current clinical experience with prolonged (oral) etoposide in cancer treatment.Anticancer research, 15 5B
- Publisher
- Springer Journals
- Copyright
- Copyright © 2003 by Adis International Limited
- Subject
- Pharmacy; Pharmacy
- ISSN
- 1175-6357
- DOI
- 10.2165/00024669-200302010-00001
- Publisher site
- See Article on Publisher Site
Abstract
Despite an initial response rate of greater than 70% to platinum-based chemotherapy, most patients with advanced epithelial ovarian cancer eventually develop and succumb to recurrent disease. Ovarian cancer patients with platinum-resistant and -refractory disease have the lowest response rates to salvage chemotherapy. Various chemotherapeutic agents, such as paclitaxel, liposomal doxorubicin, topotecan, docetaxel, platinum, etoposide, ifosfamide, gemcitabine, and vinorelbine, are available and result in response rates of 7–40%. Unfortunately, salvage therapy is not curative, and treatment is palliative. Therefore, the therapeutic choice must consider not only the best opportunity for response, but also the tolerability profile, quality-of-life issues, cost of therapy, and patient convenience. Patients should be encouraged to enroll in clinical trials evaluating novel agents and administration schedules.
Journal
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012